Abivax (ABVX) Operating Expenses (2022 - 2026)
Abivax (ABVX) posted quarterly Operating Expenses of -$67.4 million for Q1 2026, down 32.96% year-over-year from -$100.5 million in Q1 2025, and down 113.49% quarter-over-quarter from $499.6 million in Q4 2025.
Abivax (ABVX) Operating Expenses (2022 - 2026) Analysis & Trends
Abivax's Operating Expenses history runs 5 years deep, the most recent figure standing at -$67.4 million for Q1 2026.
- In Q1 2026, Operating Expenses fell 32.96% year-over-year to -$67.4 million; the TTM figure through Mar 2026 stood at $281.5 million (up 44.68% YoY), while the FY2025 annual figure was $291.7 million, up 47.23% from the prior year.
- Operating Expenses for Q1 2026 stood at -$67.4 million, down from $499.6 million in the prior quarter.
- The five-year high for Operating Expenses was $499.6 million in Q4 2025, with the low at -$96.7 million in Q3 2025.
- The 5-year median for Operating Expenses is -$49.8 million (2024), against an average of $38.8 million.
- The sharpest annual moves came in 2023 and 2024: Operating Expenses slumped 90.86% in 2023, then surged 256009642.09% in 2024.
- Abivax's Operating Expenses stood at -$70.81 in 2022, then plunged by 90.86% to -$135.14 in 2023, then surged by 256009642.09% to $346.0 million in 2024, then jumped by 44.4% to $499.6 million in 2025, then tumbled by 113.49% to -$67.4 million in 2026.
- Business Quant data shows ABVX's Operating Expenses at -$67.4 million in Q1 2026, $499.6 million in Q4 2025, and -$96.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Abivax | 9.39 Bn | 9.39 Bn | - | -67.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -67.40 Mn |
| Dec 31, 2025 | 499.57 Mn |
| Sep 30, 2025 | -96.75 Mn |
| Jun 30, 2025 | -53.87 Mn |
| Mar 31, 2025 | -50.69 Mn |
| Dec 31, 2024 | 345.97 Mn |
| Sep 30, 2024 | -56.57 Mn |
| Jun 30, 2024 | -44.10 Mn |
| Mar 31, 2024 | -49.82 Mn |
| Dec 31, 2023 | -135.14 |
| Dec 31, 2022 | -70.81 |